A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

COLONIE — Latham-based medical technology company AngioDynamics is ramping up marketing of its NanoKnife cancer treatment machine after receiving approval from the U.S. Food and Drug Administration ...

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success ...

Researchers found that prostate cancer patients with greater socioeconomic disadvantages were less likely to receive targeted therapy, and participation in the 340B program did not counteract that.

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours: San Diego, California Wednesday, ...

Gifts in Wills fund one-third of Cancer Research UK’s work. Work that supports life-saving trials for people like Alfred.

Discover Baduanjin, a traditional Chinese exercise, and a potential complementary therapy for patients with prostate cancer ...

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...